← 返回

TIL(肿瘤浸润淋巴细胞)是高级别浆液性卵巢癌中致病性 BRCA 变异相关病理特征的关键决定因素

英文原题:Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic BRCA variants in high-grade serous ovarian carcinoma.

查看英文原题

Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenic BRCA variants in high-grade serous ovarian carcinoma.

PubMed 2025/06/03(内容时间) Front Med (Lausanne) Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TILs 的存在影响病理特征对 HGSOC 中 BRCA 变异状态的诊断价值。

研究思路结论见上方概要

高级别浆液性卵巢癌(HGSOC)是一种与致病性BRCA变异相关的侵袭性癌症,可导致基因组不稳定并对聚(ADP-核糖)聚合酶抑制剂敏感。识别致病性BRCA变异对HGSOC的治疗至关重要;然而,基因检测昂贵且耗时。本研究旨在探索病理特征,特别是TIL(肿瘤浸润淋巴细胞)(TILs)的存在,作为潜在替代指标以简化基因检测的患者筛选。

我们回顾性分析了58例已知BRCA变异谱的HGSOC病例。根据单个高倍视野(HPF)中上皮内淋巴细胞数量>40或≤40,将肿瘤分为TIL阳性或TIL阴性。在这些亚组中评估了关键病理特征,包括实性、子宫内膜样和移行细胞(SET)结构模式;坏死;以及核分裂活性。采用统计分析确定这些特征与BRCA变异状态之间的关联。

在TIL阴性的HGSOC中,SET模式与致病性或可能致病性BRCA变异强烈相关(p = 0.028),成为该组中最可靠的形态学标志物。在TIL阳性的HGSOC中,低核分裂活性(每10个HPF 7个核分裂象)与致病性BRCA变异显著相关(p = 0.0002),突显了其诊断意义。TIL阴性病例中的坏死和核分裂活性以及TIL阳性病例中的SET模式与致病性BRCA变异无显著关联。对两个TIL亚组的联合分析稀释了这些关联,突显了按免疫背景对病例进行分层的重要性。

展开英文摘要原文

High-grade serous ovarian carcinoma (HGSOC), an aggressive cancer associated with pathogenic BRCA variants, causes genomic instability and sensitivity to poly (ADP-ribose) polymerase inhibitors. Identifying pathogenic BRCA variants is crucial for the treatment of HGSOC; however, genetic testing is expensive and time-consuming. This study aimed to explore pathological features, particularly the presence of tumor-infiltrating lymphocytes (TILs), as potential surrogates to streamline patient selection for genetic testing.

We retrospectively analyzed 58 cases of HGSOC with known BRCA variant profiles. Tumors were categorized as TIL-positive or TIL-negative based on the presence of > 40 or 40 intraepithelial lymphocytes in a single high-power field (HPF), respectively. Key pathological features, including solid, endometrioid, and transitional (SET) architecture patterns; necrosis; and mitotic activity, were evaluated within these subgroups. Statistical analyses were used to determine the associations between these features and BRCA variant status.

In TIL-negative HGSOCs, SET patterns were strongly associated with pathogenic or likely pathogenic BRCA variants ( p = 0.028), emerging as the most reliable morphological marker in this group. In TIL-positive HGSOCs, low mitotic activity ( 7 mitotic figure per 10 HPFs) was significantly correlated with pathogenic BRCA variants ( p = 0.0002), underscoring its diagnostic significance. Necrosis and mitotic activity in TIL-negative cases and SET patterns in TIL-positive cases were not significantly associated with pathogenic BRCA variants. Combined analysis of both TIL subgroups diluted these associations, underscoring the significance of stratifying cases by the immune context. DISCUSSION: The presence of TILs affects the diagnostic value of pathological features for BRCA variant status in HGSOC. Regarding pathogenic BRCA variants, SET patterns and low mitotic activity were identified as critical markers in TIL-negative tumors and TIL-positive tumors, respectively. These associations likely stem from interactions among genomic instability, immune response, and tumor growth. Our framework leverages these insights to prioritize high-risk cases for genetic testing, thereby optimizing resource allocation.

The presence of TILs is critical for understanding the association between pathological features and pathogenic BRCA variants in HGSOC. To improve pathogenic BRCA variant prediction, optimize genetic testing, and guide tailored intervention, our framework integrates immune context and morphological markers. This approach is especially useful in resource-limited settings and can enhance diagnostic efficiency and clinical decision-making.

论文信息

作者
Nguyen-Phan DH、Dang T、Dang AN、Huynh LTH、Nguyen PTB、Tran VQ、Ngo HTT、Doan TTP
第一作者单位
Department of Pathology and Forensic Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
通讯作者单位
Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.Taiwan
期刊
Frontiers in medicine2025
原文标识
PubMed 40529128 · DOI 10.3389/fmed.2025.1555883